布加勒斯特Fundeni临床研究所用流式细胞术监测外周血中CAR - T细胞

IF 0.5 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
D. C. Popa, Horia M. Sandu, Raluca Suciu, Valeria G. Ţica, A. Șerbănică, Ionut Şerbănică, C. Jercan, D. Coriu, A. Tanase, A. Colita
{"title":"布加勒斯特Fundeni临床研究所用流式细胞术监测外周血中CAR - T细胞","authors":"D. C. Popa, Horia M. Sandu, Raluca Suciu, Valeria G. Ţica, A. Șerbănică, Ionut Şerbănică, C. Jercan, D. Coriu, A. Tanase, A. Colita","doi":"10.2478/rrlm-2023-0019","DOIUrl":null,"url":null,"abstract":"Abstract Introduction: Over the past few years, the introduction of chimeric antigen receptor (CAR) T-cell therapy by the FDA has shown remarkable success in treating various hematologic malignancies. However, the limited response and resistance observed in some patients have hindered its broader application. Methods: At Fundeni Clinical Institute, we implemented the use of Tisagenlecleucel, a second-generation CAR T cell therapy, in April 2022. This therapy targets CD19, an antigen expressed in all B lineage cells. To assess the cellular kinetics of CAR T cell-treated patients and conduct further research, we developed an 8-color/10-parameter flow cytometry tube. This tube utilizes a biotinylated CD19 CAR Detection Reagent with high sensitivity and specificity for CD19-targeted CARs, enabling us to effectively separate CAR T cells from normal T cells. Results: Through immunophenotyping, we successfully identified circulating CAR T cells and distinguished various subtypes of immune cells in the peripheral blood of infused patients. Furthermore, we validated the accuracy of our flow cytometry panel for monitoring the progress of CAR T cell therapy. Conclusions: This paper highlights the implementation of our flow cytometry monitoring panel for CAR T cells following Tisagenlecleucel therapy at Fundeni Clinical Institute. Our practical solution allows us to identify CAR T cells, assess B cell presence, and characterize different T cell subtypes in our patients. This standardized approach enhances our understanding and monitoring of CAR T cell therapy, leading to improved patient care and outcomes.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"22 1","pages":"175 - 184"},"PeriodicalIF":0.5000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest\",\"authors\":\"D. C. Popa, Horia M. Sandu, Raluca Suciu, Valeria G. Ţica, A. Șerbănică, Ionut Şerbănică, C. Jercan, D. Coriu, A. Tanase, A. Colita\",\"doi\":\"10.2478/rrlm-2023-0019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Introduction: Over the past few years, the introduction of chimeric antigen receptor (CAR) T-cell therapy by the FDA has shown remarkable success in treating various hematologic malignancies. However, the limited response and resistance observed in some patients have hindered its broader application. Methods: At Fundeni Clinical Institute, we implemented the use of Tisagenlecleucel, a second-generation CAR T cell therapy, in April 2022. This therapy targets CD19, an antigen expressed in all B lineage cells. To assess the cellular kinetics of CAR T cell-treated patients and conduct further research, we developed an 8-color/10-parameter flow cytometry tube. This tube utilizes a biotinylated CD19 CAR Detection Reagent with high sensitivity and specificity for CD19-targeted CARs, enabling us to effectively separate CAR T cells from normal T cells. Results: Through immunophenotyping, we successfully identified circulating CAR T cells and distinguished various subtypes of immune cells in the peripheral blood of infused patients. Furthermore, we validated the accuracy of our flow cytometry panel for monitoring the progress of CAR T cell therapy. Conclusions: This paper highlights the implementation of our flow cytometry monitoring panel for CAR T cells following Tisagenlecleucel therapy at Fundeni Clinical Institute. Our practical solution allows us to identify CAR T cells, assess B cell presence, and characterize different T cell subtypes in our patients. This standardized approach enhances our understanding and monitoring of CAR T cell therapy, leading to improved patient care and outcomes.\",\"PeriodicalId\":49599,\"journal\":{\"name\":\"Revista Romana De Medicina De Laborator\",\"volume\":\"22 1\",\"pages\":\"175 - 184\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Romana De Medicina De Laborator\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/rrlm-2023-0019\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Romana De Medicina De Laborator","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/rrlm-2023-0019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

摘要简介:在过去的几年中,FDA引入嵌合抗原受体(CAR) t细胞疗法在治疗各种血液恶性肿瘤方面取得了显着的成功。然而,在一些患者中观察到的有限的反应和耐药性阻碍了其更广泛的应用。方法:在Fundeni临床研究所,我们于2022年4月实施了第二代CAR - T细胞疗法Tisagenlecleucel的使用。这种疗法靶向CD19,一种在所有B系细胞中表达的抗原。为了评估CAR - T细胞治疗患者的细胞动力学并进行进一步的研究,我们开发了一种8色/10参数的流式细胞术管。该试管采用生物素化CD19 CAR检测试剂,对CD19靶向CAR具有高灵敏度和特异性,使我们能够有效地分离CAR - T细胞和正常T细胞。结果:通过免疫分型,我们成功鉴定了循环CAR - T细胞,并区分了输注患者外周血中的各种免疫细胞亚型。此外,我们验证了流式细胞仪面板用于监测CAR - T细胞治疗进展的准确性。结论:本文强调了我们在Fundeni临床研究所对Tisagenlecleucel治疗后的CAR - T细胞流式细胞术监测面板的实施。我们的实用解决方案使我们能够识别CAR - T细胞,评估B细胞的存在,并在我们的患者中表征不同的T细胞亚型。这种标准化的方法增强了我们对CAR - T细胞疗法的理解和监测,从而改善了患者的护理和结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest
Abstract Introduction: Over the past few years, the introduction of chimeric antigen receptor (CAR) T-cell therapy by the FDA has shown remarkable success in treating various hematologic malignancies. However, the limited response and resistance observed in some patients have hindered its broader application. Methods: At Fundeni Clinical Institute, we implemented the use of Tisagenlecleucel, a second-generation CAR T cell therapy, in April 2022. This therapy targets CD19, an antigen expressed in all B lineage cells. To assess the cellular kinetics of CAR T cell-treated patients and conduct further research, we developed an 8-color/10-parameter flow cytometry tube. This tube utilizes a biotinylated CD19 CAR Detection Reagent with high sensitivity and specificity for CD19-targeted CARs, enabling us to effectively separate CAR T cells from normal T cells. Results: Through immunophenotyping, we successfully identified circulating CAR T cells and distinguished various subtypes of immune cells in the peripheral blood of infused patients. Furthermore, we validated the accuracy of our flow cytometry panel for monitoring the progress of CAR T cell therapy. Conclusions: This paper highlights the implementation of our flow cytometry monitoring panel for CAR T cells following Tisagenlecleucel therapy at Fundeni Clinical Institute. Our practical solution allows us to identify CAR T cells, assess B cell presence, and characterize different T cell subtypes in our patients. This standardized approach enhances our understanding and monitoring of CAR T cell therapy, leading to improved patient care and outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Romana De Medicina De Laborator
Revista Romana De Medicina De Laborator MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
0.31
自引率
20.00%
发文量
43
审稿时长
>12 weeks
期刊介绍: The aim of the journal is to publish new information that would lead to a better understanding of biological mechanisms of production of human diseases, their prevention and diagnosis as early as possible and to monitor therapy and the development of the health of patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信